LOW DOSE ASPIRIN FOR PREVENTION OF PRE-ECLAMPSIA AMONG WOMEN AT HIGH RISK
Article Sidebar
Main Article Content
Abstract
Background: Pre-eclampsia affects up to 10% pregnancies worldwide and is one of the foremost causes of poor maternal & fetal outcome. Prophylaxis with low-dose aspirin has been recommended to prevent preeclampsia in women at high risk. Therefore, in this study we intent to evaluate the effectiveness of aspirin for the prevention of preeclampsia and other adverse maternal and neonatal outcomes among identified women at high risk by NICE guideline in Chiang Rai
Methods: An Observational retrospective cohort study was conducted. The data has collected from 2016 to 2019 by assessing the database of Chiang rai Prachanukroh hospital. Total 406 women were recruited ,190 women were given 81 mg aspirin orally from 10-28 weeks of gestation until 36 weeks of gestation while 216 women received no aspirin.
Results: The mean age of patients was 32.05 years and 32.75 years in the aspirin and control group, respectively. Chronic hypertension was the most identified population (69.70%).The incidence of pre-eclampsia in the aspirin group was less than control group statistically significant ,42 (22.11%) and 77 (35.65 %) [RR 0.48 (0.29-0.77) ,p= 0.002] NNT 7.2 In For subgroup analysis ,women with chronic hypertension the incidence of preeclampsia was also decreased in aspirin group,24(12.63%) and57(26.39%)[RR 0.59(0.39-0.89) , p=0.005].The onset of preeclampsia almost was late-onset preeclampsia 34.36 weeks of gestation and 35.56 weeks of gestation in the aspirin group and control group, respectively(p=0.076).The incidence of infant small for gestational age was slightly increased in aspirin group 26.84% compare with 23.61% in control group but did not reach a statistically significant difference(p=0.939) In addition ,the incidence of postpartum hemorrhage ,perinatal death ,birth asphyxia ,preterm birth were similar in the aspirin and control groups.
ConclusionS and discussions: In our study, Low dose aspirin has significant effect on women at high risk for prevention of pre-eclampsia and did not increased adverse perinatal outcomes.
Article Details
References
1. Mol BWJ, Roberts CT, Thangaratinam S, Magee LA, de Groot CJM, Hofmeyr GJ. Pre-eclampsia. Lancet. 2016;387:999–1011.
2. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980–2010: age-period-cohort analysis. BMJ. 2013;347:f6564.
3. Beaufils M, Donsimoni R, Uzan S, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet. 1985;1:840–2.
4. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia
5. National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders during Pregnancy. London: RCOG Press, 2010.
6. Rolnik DL, Wright D, Poon LC et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med 2017; 377: 613–622.
7. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs. 2017 Nov;77(17):1819-1831. doi: 10.1007/s40265-017-0823-0. PMID: 29039130; PMCID: PMC5681618.
8. World Health Organization (WHO). WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. Geneva: WHO; 2011.
9. Duley L, Henderson-Smart DJ, Meher S, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev. 2007;(2):CD004659.
10. แนวทางการปฏิบัติ ของราชวิทยาลัยสูตินรีแพทย์แห่งประเทศไทย เรื่อง การดูแลภาวะครรภ์เป็นพิษ RTCOG Clinical Practice Guideline Management of Preeclampsia and Eclampsia พศ. 2558
11. NICE guideline NG133 : Hypertension in pregnancy diagnosis and management
12. Poon LC, Wright D, Rolnik DL, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. Am J Obstet Gynecol 2017;217:585.e1-5.
